ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer

Jennifer Yu, Feng Gao, Vicki Klimberg, Julie A. Margenthaler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction. Triple-negative breast cancer (TNBC) has a poorer prognosis; the factors that contribute to this remain unclear. We hypothesized that TNBC is associated with ABO blood type/Rh factors that account for differences in survival. Methods. We identified 468 patients with stage I-III TNBC [estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2 nonamplified]. Patient/tumor characteristics, treatments, and outcomes were obtained. Data were examined for associations with specific ABO blood type/Rh factors. Descriptive statistics and X2 analysis were utilized for data summary and comparisons. Results. Of 468 TNBC patients, 283 had known ABO blood type [122 (43 %) O, 108 (38 %) A, 39 (14 %) B, and 14 (5 %) AB] and Rh factor [253 (89 %) positive and 30 (11 %) negative]. Mean patient age was 53.7 ± 12.5 years, and median follow-up was 30.2 ± 20.5 months. The incidence of each ABO blood type/Rh factor in our TNBC cohort was not different from the general population or a cohort of ER-positive breast cancers (P>0.05). Compared with patients with blood type O, there was no difference in breast cancer-specific mortality for type A [hazard ratio (HR) 0.906; 95 % confidence interval (CI) 0.554-1.481], type B (HR 1.534; 95 % CI 0.792-2.972), or type AB (HR 0.488; 95 % CI 0.113-2.106). Compared with women with negative Rh, there was no difference in breast cancerspecific mortality for women with positive Rh (HR 1.161; 95 % CI 0.568-2.374). Conclusions. TNBC was not associated with a specific ABO blood type or Rh factor. Our results failed to demonstrate an association between ABO blood type/Rh factor and breast cancer mortality in patients with TNBC.

Original languageEnglish (US)
Pages (from-to)3159-3164
Number of pages6
JournalAnnals of Surgical Oncology
Volume19
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Rh-Hr Blood-Group System
Triple Negative Breast Neoplasms
Incidence
Confidence Intervals
Breast Neoplasms
Estrogen Receptors
Mortality
ABO Blood-Group System
Progesterone Receptors
Breast
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer. / Yu, Jennifer; Gao, Feng; Klimberg, Vicki; Margenthaler, Julie A.

In: Annals of Surgical Oncology, Vol. 19, No. 10, 10.2012, p. 3159-3164.

Research output: Contribution to journalArticle

@article{cc6dac5f6c25436483769023f3f21b69,
title = "ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer",
abstract = "Introduction. Triple-negative breast cancer (TNBC) has a poorer prognosis; the factors that contribute to this remain unclear. We hypothesized that TNBC is associated with ABO blood type/Rh factors that account for differences in survival. Methods. We identified 468 patients with stage I-III TNBC [estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2 nonamplified]. Patient/tumor characteristics, treatments, and outcomes were obtained. Data were examined for associations with specific ABO blood type/Rh factors. Descriptive statistics and X2 analysis were utilized for data summary and comparisons. Results. Of 468 TNBC patients, 283 had known ABO blood type [122 (43 {\%}) O, 108 (38 {\%}) A, 39 (14 {\%}) B, and 14 (5 {\%}) AB] and Rh factor [253 (89 {\%}) positive and 30 (11 {\%}) negative]. Mean patient age was 53.7 ± 12.5 years, and median follow-up was 30.2 ± 20.5 months. The incidence of each ABO blood type/Rh factor in our TNBC cohort was not different from the general population or a cohort of ER-positive breast cancers (P>0.05). Compared with patients with blood type O, there was no difference in breast cancer-specific mortality for type A [hazard ratio (HR) 0.906; 95 {\%} confidence interval (CI) 0.554-1.481], type B (HR 1.534; 95 {\%} CI 0.792-2.972), or type AB (HR 0.488; 95 {\%} CI 0.113-2.106). Compared with women with negative Rh, there was no difference in breast cancerspecific mortality for women with positive Rh (HR 1.161; 95 {\%} CI 0.568-2.374). Conclusions. TNBC was not associated with a specific ABO blood type or Rh factor. Our results failed to demonstrate an association between ABO blood type/Rh factor and breast cancer mortality in patients with TNBC.",
author = "Jennifer Yu and Feng Gao and Vicki Klimberg and Margenthaler, {Julie A.}",
year = "2012",
month = "10",
doi = "10.1245/s10434-012-2533-x",
language = "English (US)",
volume = "19",
pages = "3159--3164",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer

AU - Yu, Jennifer

AU - Gao, Feng

AU - Klimberg, Vicki

AU - Margenthaler, Julie A.

PY - 2012/10

Y1 - 2012/10

N2 - Introduction. Triple-negative breast cancer (TNBC) has a poorer prognosis; the factors that contribute to this remain unclear. We hypothesized that TNBC is associated with ABO blood type/Rh factors that account for differences in survival. Methods. We identified 468 patients with stage I-III TNBC [estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2 nonamplified]. Patient/tumor characteristics, treatments, and outcomes were obtained. Data were examined for associations with specific ABO blood type/Rh factors. Descriptive statistics and X2 analysis were utilized for data summary and comparisons. Results. Of 468 TNBC patients, 283 had known ABO blood type [122 (43 %) O, 108 (38 %) A, 39 (14 %) B, and 14 (5 %) AB] and Rh factor [253 (89 %) positive and 30 (11 %) negative]. Mean patient age was 53.7 ± 12.5 years, and median follow-up was 30.2 ± 20.5 months. The incidence of each ABO blood type/Rh factor in our TNBC cohort was not different from the general population or a cohort of ER-positive breast cancers (P>0.05). Compared with patients with blood type O, there was no difference in breast cancer-specific mortality for type A [hazard ratio (HR) 0.906; 95 % confidence interval (CI) 0.554-1.481], type B (HR 1.534; 95 % CI 0.792-2.972), or type AB (HR 0.488; 95 % CI 0.113-2.106). Compared with women with negative Rh, there was no difference in breast cancerspecific mortality for women with positive Rh (HR 1.161; 95 % CI 0.568-2.374). Conclusions. TNBC was not associated with a specific ABO blood type or Rh factor. Our results failed to demonstrate an association between ABO blood type/Rh factor and breast cancer mortality in patients with TNBC.

AB - Introduction. Triple-negative breast cancer (TNBC) has a poorer prognosis; the factors that contribute to this remain unclear. We hypothesized that TNBC is associated with ABO blood type/Rh factors that account for differences in survival. Methods. We identified 468 patients with stage I-III TNBC [estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2 nonamplified]. Patient/tumor characteristics, treatments, and outcomes were obtained. Data were examined for associations with specific ABO blood type/Rh factors. Descriptive statistics and X2 analysis were utilized for data summary and comparisons. Results. Of 468 TNBC patients, 283 had known ABO blood type [122 (43 %) O, 108 (38 %) A, 39 (14 %) B, and 14 (5 %) AB] and Rh factor [253 (89 %) positive and 30 (11 %) negative]. Mean patient age was 53.7 ± 12.5 years, and median follow-up was 30.2 ± 20.5 months. The incidence of each ABO blood type/Rh factor in our TNBC cohort was not different from the general population or a cohort of ER-positive breast cancers (P>0.05). Compared with patients with blood type O, there was no difference in breast cancer-specific mortality for type A [hazard ratio (HR) 0.906; 95 % confidence interval (CI) 0.554-1.481], type B (HR 1.534; 95 % CI 0.792-2.972), or type AB (HR 0.488; 95 % CI 0.113-2.106). Compared with women with negative Rh, there was no difference in breast cancerspecific mortality for women with positive Rh (HR 1.161; 95 % CI 0.568-2.374). Conclusions. TNBC was not associated with a specific ABO blood type or Rh factor. Our results failed to demonstrate an association between ABO blood type/Rh factor and breast cancer mortality in patients with TNBC.

UR - http://www.scopus.com/inward/record.url?scp=84868200591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868200591&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2533-x

DO - 10.1245/s10434-012-2533-x

M3 - Article

VL - 19

SP - 3159

EP - 3164

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -